{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Showing 125031 - 125036 of 125036 results
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Source:
Imdevimab by Regeneron Pharmaceuticals, Inc.
(2020)
Source URL:
First approved in 2020
Source:
Imdevimab by Regeneron Pharmaceuticals, Inc.
Source URL:
Class:
CONCEPT
Status:
Possibly Marketed Outside US
Class:
CONCEPT
YTTRIUM Y-90 (YTRACIS®, YTTRIGA®) is a radioactive form of the chemical element yttrium. It is used for radiolabelling other medicines. An example of its use is the treatment of some type of tumors, where the radiolabelled medicine carries the radioactivity to the site of a tumor to destroy the tumor cells.
Status:
Possibly Marketed Outside US
Source:
NCT03151707: Phase 4 Interventional Recruiting Healthy
(2017)
Source URL:
Class:
CONCEPT